Prof Robertson talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about fulvestrant (500mg dose) in comparison to the aromatase inhibitor, anastrozole, when used as a first-line treatment for hormone receptor positive breast cancer. Follow-up data from the FIRST (FASLODEX fIRst line Study comparing endocrine Treatments) trial - a randomised, open-label, phase II trial in postmenopausal women with locally advanced or metastatic disease - showed a 34% reduction in risk of progression with fulvestrant 500mg compared with anastrozole. Prof Robertson considers impact in the clinic and potential future research.